Mivobulin free base | CI-980 | CAS#122332-18-7 | 126268-81-3 | tubulin inhibitor

MedKoo Cat#: 205980 | Name: Mivobulin free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mivobulin, also known as CI-980, is a synthetic colchicine analogue with potential antineoplastic activity. Mivobulin isethionate binds to tubulin, thereby inhibiting microtubule polymerization and mitosis.

Chemical Structure

Mivobulin free base

CAS#122332-18-7 (free base)

Theoretical Analysis

MedKoo Cat#: 205980

Name: Mivobulin free base

CAS#: 122332-18-7 (free base)

Chemical Formula: C17H19N5O2

Exact Mass: 325.1539

Molecular Weight: 325.37

Elemental Analysis: C, 62.75; H, 5.89; N, 21.52; O, 9.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

126268-81-3 (Isethionate) 122332-18-7 (free base)

Synonym

Mivobulin free base; CI-980; NSC-613863; NSC-635370; NSC-613862; NSC-350386; CI980; NSC613863; NSC635370; NSC613862; NSC350386.

IUPAC/Chemical Name

(S)-ethyl (5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl)carbamate

InChi Key

XXBDOTXPQDVHIP-JTQLQIEISA-N

InChi Code

InChI=1S/C17H19N5O2/c1-3-24-17(23)21-13-9-12-15(16(18)20-13)22-14(10(2)19-12)11-7-5-4-6-8-11/h4-10,19H,3H2,1-2H3,(H3,18,20,21,23)/t10-/m0/s1

SMILES Code

O=C(OCC)NC1=CC2=C(C(N)=N1)N=C(C3=CC=CC=C3)[C@H](C)N2

Appearance

Solid powder

Purity

>98%

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 122332-18-7 (Mivobulin free base) 126268-81-3 (Mivobulin Isethionate)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 325.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WK. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002;20(7-8):948-54. PubMed PMID: 12449727. 2: Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD; Ohio State University Phase II Research Consortium Study.. A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study. Cancer Invest. 2002;20(2):192-8. PubMed PMID: 11901539. 3: Whitehead RP, Unger JM, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Invest New Drugs. 2001;19(3):239-43. PubMed PMID: 11561681. 4: Ryan CW, Shulman KL, Richards JM, Kugler JW, Sosman JA, Ansari RH, Vokes EE, Vogelzang NJ. CI-980 in advanced melanoma and hormone refractory prostate cancer. Invest New Drugs. 2000 May;18(2):187-91. PubMed PMID: 10857996. 5: Bernstein ML, Baruchel S, Devine S, Markoglou N, Wainer IW, Williams M, Blaney S, Moghrabi A, Winick N, Vietti T. Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):494-500. PubMed PMID: 10598660. 6: Patel SR, Burgess MA, Papadopolous NE, Sidhu G, Gray R, Plager C, Jenkins J, Benjamin RS. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest New Drugs. 1998;16(1):87-92. PubMed PMID: 9740549. 7: Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, Freedman RS, Forman A, Conrad CA, Grove W, Grothey A, Kavanagh JJ. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs. 1998 Jun;9(5):405-9. PubMed PMID: 9660537. 8: Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, Ajani J. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol. 1997 Dec;20(6):573-6. PubMed PMID: 9391543. 9: Markoglou N, Wainer IW. Determination of the anticancer agent CI-980 in plasma by achiral liquid chromatography on a Pirkle-type stationary phase. J Chromatogr B Biomed Sci Appl. 1997 Jun 6;693(2):493-7. PubMed PMID: 9210458. 10: Wright J, Ho PT, Phillips PH, Cheson BD. Clinical Trials. Referral resource Clinical trials using CI-980 (mivobulin isethionate). Oncology (Williston Park). 1997 May;11(5):643-4. PubMed PMID: 9159791. 11: Meyers CA, Kudelka AP, Conrad CA, Gelke CK, Grove W, Pazdur R. Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res. 1997 Mar;3(3):419-22. PubMed PMID: 9815700. 12: Rowinsky EK, Long GS, Noe DA, Grochow LB, Bowling MK, Sartorius SE, Donehower RC. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res. 1997 Mar;3(3):401-7. PubMed PMID: 9815698. 13: Sklarin NT, Lathia CD, Benson L, Grove WR, Thomas S, Roca J, Einzig AI, Wiernik PH. A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Invest New Drugs. 1997;15(3):235-46. PubMed PMID: 9387046. 14: Pérez O, Valenzuela C, Delpón E, Tamargo J. Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles. Br J Pharmacol. 1997 Jan;120(2):187-92. PubMed PMID: 9117108; PubMed Central PMCID: PMC1564362. 15: Barbier P, Peyrot V, Dumortier C, D'Hoore A, Rener GA, Engelborghs Y. Kinetics of association and dissociation of two enantiomers, NSC 613863 (R)-(+) and NSC 613862 (S)-(-) (CI 980), to tubulin. Biochemistry. 1996 Feb 13;35(6):2008-15. PubMed PMID: 8639685. 16: Hook KE, Przybranowski SA, Leopold WR. Cellular transport of CI-980. Invest New Drugs. 1996;14(4):341-7. PubMed PMID: 9157068. 17: Bullen WW, Whitfield LR, Walter GA, Brodfuehrer JI. High-performance liquid chromatographic assay for CI-980, a novel 1-deaza-7,8-dihydropteridine anticancer agent, in human plasma and urine. J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):141-51. PubMed PMID: 7550971. 18: Chevalier P, Kuznetsov V, Robinson RB, Rosen MR. Tubulin binding agent CI-980 has positive inotropic and local anesthetic actions. J Cardiovasc Pharmacol. 1994 Jun;23(6):944-51. PubMed PMID: 7523787. 19: de Ines C, Leynadier D, Barasoain I, Peyrot V, Garcia P, Briand C, Rener GA, Temple C Jr. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. Cancer Res. 1994 Jan 1;54(1):75-84. PubMed PMID: 8261466. 20: MacDonald JR, Pegg DG. Extravasation injury potential of CI-980, a novel synthetic mitotic inhibitor. Cancer Chemother Pharmacol. 1993;32(5):365-7. PubMed PMID: 8339386.